NicOx Stock Price, News & Analysis (OTCMKTS:NICXF)

0.00 (0.00 %)
(As of 09/20/2019 04:00 PM ET)
Today's Range
Now: $5.84
50-Day Range
MA: $5.12
52-Week Range
Now: $5.84
Average Volume51 shs
Market Capitalization$172.63 million
P/E RatioN/A
Dividend YieldN/A
Nicox SA, an ophthalmic company, researches, develops, and markets therapies that target various ophthalmic conditions in France and internationally. The company's product pipeline includes VyzultaTM, an intraocular pressure-lowering treatment; and NCX 470, a nitric oxide (NO)-donating candidate to treat glaucoma, as well as stand-alone NO donors for specific applications in ophthalmic diseases. Read More…

Industry, Sector and Symbol

Industry Private households
Previous SymbolNASDAQ:NICXF



Sales & Book Value

Annual Sales$20,000.00



Market Cap$172.63 million
Next Earnings DateN/A
OptionableNot Optionable

Receive NICXF News and Ratings via Email

Sign-up to receive the latest news and ratings for NICXF and its competitors with MarketBeat's FREE daily newsletter.

NicOx (OTCMKTS:NICXF) Frequently Asked Questions

What is NicOx's stock symbol?

NicOx trades on the OTCMKTS under the ticker symbol "NICXF."

What is the consensus analysts' recommendation for NicOx?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NicOx in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for NicOx.

Has NicOx been receiving favorable news coverage?

Media coverage about NICXF stock has been trending negative recently, InfoTrie reports. The research group identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. NicOx earned a coverage optimism score of -2.9 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the next few days. View News Stories for NicOx.

Who are some of NicOx's key competitors?

What other stocks do shareholders of NicOx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NicOx investors own include Aerie Pharmaceuticals (AERI), CGG (CGG), HomeStreet (HMST), Quidel (QDEL), Scorpio Bulkers (SALT), Valero Energy Partners (VLP), Innate Pharma (IPHYF), Synairgen (SNG), Standard Life Aberdeen (SLA) and Rightmove (RMV).

Who are NicOx's key executives?

NicOx's management team includes the folowing people:
  • Mr. Michele Garufi, Co-Founder, Chairman & CEO (Age 65)
  • Ms. Sandrine Gestin, VP of Fin. (Age 52)
  • Dr. Michael V. W. Bergamini, Chief Scientific Advisor (Age 72)
  • Mrs. Emmanuelle Pierry, Sr. Director of Legal Affairs
  • Dr. Gavin Spencer, Exec. VP, Chief Bus. Officer & Head of Corp. Devel. (Age 49)

How do I buy shares of NicOx?

Shares of NICXF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is NicOx's stock price today?

One share of NICXF stock can currently be purchased for approximately $5.84.

How big of a company is NicOx?

NicOx has a market capitalization of $172.63 million and generates $20,000.00 in revenue each year. NicOx employs 31 workers across the globe.View Additional Information About NicOx.

What is NicOx's official website?

The official website for NicOx is

How can I contact NicOx?

NicOx's mailing address is Drakkar 2 - Batiment D 2405 route des Dolines - CS 10313 Sophia Antipolis Cedex, Valbonne I0, 06560. The company can be reached via phone at 33-4-97-24-53-00.

MarketBeat Community Rating for NicOx (OTCMKTS NICXF)

Community Ranking:  1.8 out of 5 (star)
Outperform Votes:  91 (Vote Outperform)
Underperform Votes:  158 (Vote Underperform)
Total Votes:  249
MarketBeat's community ratings are surveys of what our community members think about NicOx and other stocks. Vote "Outperform" if you believe NICXF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NICXF will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/20/2019 by Staff

Featured Article: Penny Stocks

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel